Search

Your search keyword '"Potito Rosario Scalzulli"' showing total 5 results
Start Over Author "Potito Rosario Scalzulli" Publisher springer science and business media llc
5 results on '"Potito Rosario Scalzulli"'

1. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

Author

Francesco Gaudio, Giacomo Loseto, Valentina Bozzoli, Potito Rosario Scalzulli, Anna Maria Mazzone, Lorenzo Tonialini, Vincenza Fesce, Giovanni Quintana, Gaetano De Santis, Pierluigi Masciopinto, Elena Arcuti, Felice Clemente, Stefania Scardino, Giuseppe Tarantini, Domenico Pastore, Lorella Melillo, Vincenzo Pavone, Alessandro Maggi, Angelo Michele Carella, Nicola Di Renzo, Attilio Guarini, and Pellegrino Musto

Subjects
Hematology, General Medicine
Published
2023

2. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)

Author

Angela Melpignano, Nicola Cascavilla, Vincenzo Pavone, Giuseppe Tarantini, Giorgina Specchia, Giulia Palazzo, Prete Eleonora, Potito Rosario Scalzulli, Patrizio Mazza, Daniela Carlino, Anna Mele, Giovanni Quintana, Tommasina Perrone, Francesco Gaudio, Nicola Di Renzo, Silvana Capalbo, Attilio Guarini, and Giacomo Loseto

Subjects
Male, Immunoconjugates, Salvage therapy, Kaplan-Meier Estimate, Gastroenterology, 0302 clinical medicine, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy, Brentuximab vedotin, Aged, 80 and over, Brentuximab Vedotin, Hematology, Remission Induction, Peripheral Nervous System Diseases, General Medicine, Middle Aged, Allografts, Combined Modality Therapy, Hodgkin Disease, Treatment Outcome, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Anemia, Ki-1 Antigen, Antineoplastic Agents, Neutropenia, Transplantation, Autologous, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Salvage Therapy, business.industry, medicine.disease, Hematologic Diseases, Regimen, Drug Evaluation, business, Stem Cell Transplantation, 030215 immunology
Abstract

Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64%) were treated with BV as bridge to transplant:16 (23%) patients as bridge to ASCT and 29 (41%) as bridge to alloSCT. Twenty-five patients (36%), not eligible for transplant, received BV as salvage treatment. The ORR was 59% (CR 26%). The ORR in transplant naive patients was 75% (CR 31%). In patients treated with BV as bridge to alloSCT, the ORR was 62% (CR 24%). In a multivariate analysis, the ORR was lower in refractory patients (p

Published
2018

3. Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy

Author

Cosima Battista, Nicola Cascavilla, Giovanna D'Andrea, Caterina Buquicchio, Angelo Ostuni, Maurizio Brigante, Giulio Giordano, Silvia Piano, Filippo Aucella, Potito Rosario Scalzulli, Elvira Grandone, Giovanni Luca Tiscia, Prudenza Ranieri, Livio Tullo, Filomena Cappucci, Antonio Abrescia, Barbara Infante, and Bruno Di Paolo

Subjects
medicine.medical_specialty, Thrombotic thrombocytopenic purpura, ADAMTS13 Protein, 030204 cardiovascular system & hematology, Risk Assessment, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Pathognomonic, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, Aged, Purpura, Thrombotic Thrombocytopenic, Receiver operating characteristic, Thrombotic Microangiopathies, business.industry, Area under the curve, Hematology, Middle Aged, medicine.disease, Thrombosis, ADAMTS13, Italy, ROC Curve, 030220 oncology & carcinogenesis, Hemostasis, Cohort, cardiovascular system, Cardiology and Cardiovascular Medicine, business
Abstract

Severe ADAMTS13 deficiency (activity

Published
2018

4. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm’s tumor 1 levels

Author

Maria Marta Minervini, Giovanni Rossi, Nicola Pio Sinisi, Nicola Cascavilla, Lorella Melillo, Francesco Di Nardo, Daniela Valente, Gianni Perla, Chiara De Waure, and Potito Rosario Scalzulli

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Genes, Wilms Tumor, Neoplasm, Residual, Multivariate analysis, Myeloid, Biology, Wilms Tumor, Disease-Free Survival, Young Adult, Predictive Value of Tests, Log clearance, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Univariate analysis, Acute myeloid leukemia, Hematology, Minimal residual disease, Myeloid leukemia, General Medicine, Middle Aged, Flow Cytometry, WT1-RNA, medicine.disease, Kidney Neoplasms, Multiparameter flow cytometry, body regions, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, Predictive value of tests, Immunology, Female
Abstract

In acute myeloid leukemia (AML), the detection of minimal residual disease (MRD) as well as the degree of log clearance similarly identifies patients with poor prognosis. No comparison was provided between the two approaches in order to identify the best one to monitor follow-up patients. In this study, MRD and clearance were assessed by both multiparameter flow cytometry (MFC) and WT1 expression at different time points on 45 AML patients achieving complete remission. Our results by WT1 expression showed that log clearance lower than 1.96 after induction predicted the recurrence better than MRD higher than 77.0 copies WT1/10(4) ABL. Conversely, on MFC, MRD higher than 0.2 % after consolidation was more predictive than log clearance below 2.64. At univariate and multivariate analysis, positive MRD values and log clearance below the optimal cutoffs were associated with a shorter disease-free survival (DFS). At the univariate analysis, positive MRD values were also associated with overall survival (OS). Therefore, post-induction log clearance by WT1 and post-consolidation MRD by MFC represented the most informative approaches to identify the relapse. At the optimal timing of assessment, positive MRD and log-clearance values lower than calculated thresholds similarly predicted an adverse prognosis in AML.

Published
2014

5. Ciculating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield

Author

Nicola Cascavilla, Giovanni D'Arena, N. Dello Iacono, Pellegrino Musto, Potito Rosario Scalzulli, and Mario Carotenuto

Subjects
Transplantation, Quality (physics), business.industry, Cell number, Yield (chemistry), Statistics, Medicine, Single parameter, Hematology, business
Abstract

Ciculating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results